Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

BACKGROUND: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the eff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400121/
https://ncbi.nlm.nih.gov/pubmed/30881026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182259
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars